These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 10620209)

  • 1. ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies1.
    Perna A; Ruggenenti P; Testa A; Spoto B; Benini R; Misefari V; Remuzzi G; Zoccali C
    Kidney Int; 2000 Jan; 57(1):274-81. PubMed ID: 10620209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen).
    Ruggenenti P; Perna A; Zoccali C; Gherardi G; Benini R; Testa A; Remuzzi G
    J Am Soc Nephrol; 2000 Jan; 11(1):88-96. PubMed ID: 10616844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.
    Ruggenenti P; Perna A; Gherardi G; Benini R; Remuzzi G
    Am J Kidney Dis; 2000 Jun; 35(6):1155-65. PubMed ID: 10845831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
    Lancet; 1997 Jun; 349(9069):1857-63. PubMed ID: 9217756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of angiotensin-converting enzyme gene polymorphism on proteinuria and arterial hypertension.
    Zivko M; Kusec R; Galesić K
    Coll Antropol; 2013 Sep; 37(3):765-70. PubMed ID: 24308214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiproteinuric effect of losartan in non-diabetic renal disease is not dependent on ACE insertion/deletion polymorphism.
    Park HC; Choi HY; Kim BS; Kang SW; Choi KH; Ha SK; Lee HY; Han DS
    Kidney Blood Press Res; 2006; 29(4):216-24. PubMed ID: 16960460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism.
    Vegter S; Perna A; Hiddema W; Ruggenenti P; Remuzzi G; Navis G; Postma MJ
    Pharmacogenet Genomics; 2009 Sep; 19(9):695-703. PubMed ID: 19696696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: role of sodium status.
    van der Kleij FG; Schmidt A; Navis GJ; Haas M; Yilmaz N; de Jong PE; Mayer G; de Zeeuw D
    Kidney Int Suppl; 1997 Dec; 63():S23-6. PubMed ID: 9407415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.
    Ruggenenti P; Perna A; Gherardi G; Garini G; Zoccali C; Salvadori M; Scolari F; Schena FP; Remuzzi G
    Lancet; 1999 Jul; 354(9176):359-64. PubMed ID: 10437863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria.
    Ruggenenti P; Perna A; Remuzzi G;
    Kidney Int; 2003 Jun; 63(6):2254-61. PubMed ID: 12753315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Polymorphism studies of angiotensin converting enzyme gene in chronic glomerulonephritis].
    Kutyrina IM; Tareeva IE; Nosikov VV; Kamyshova ES; Gorashko NM; Chistiakov DA; Okonova EB; Troepol'skaia OV
    Ter Arkh; 1999; 71(6):30-4. PubMed ID: 10420452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).
    Ruggenenti P; Perna A; Mosconi L; Pisoni R; Remuzzi G
    Kidney Int; 1998 May; 53(5):1209-16. PubMed ID: 9573535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACE DD genotype is more susceptible than ACE II and ID genotypes to the antiproteinuric effect of ACE inhibitors in patients with proteinuric non-insulin-dependent diabetes mellitus.
    Ha SK; Yong Lee S; Su Park H; Ho Shin J; Jung Kim S; Hun Kim D; Rae Kim K; Yung Lee H; Suk Han D
    Nephrol Dial Transplant; 2000 Oct; 15(10):1617-23. PubMed ID: 11007831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of renin-angiotensin system genotypes on the antiproteinuric response to high doses of olmesartan in non-diabetic proteinuric nephropathies.
    Goyache-Goñi B; Aranda-Lara P; Reyes-Engels A; Frutos-Sanz MA; Hernández-Marrero D
    Nefrologia; 2013 Nov; 33(6):771-8. PubMed ID: 24241364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy.
    Ruggenenti P; Perna A; Remuzzi G
    J Am Soc Nephrol; 2001 Dec; 12(12):2832-2837. PubMed ID: 11729254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease. Austrian Study Group of the Effects of Enalapril Treatment in Proteinuric Renal Disease.
    Haas M; Yilmaz N; Schmidt A; Neyer U; Arneitz K; Stummvoll HK; Wallner M; Auinger M; Arias I; Schneider B; Mayer G
    Kidney Blood Press Res; 1998; 21(1):66-9. PubMed ID: 9661139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ACE polymorphism does not determine short-term renal response to ACE-inhibition in proteinuric patients.
    van der Kleij FG; Navis GJ; Gansevoort RT; Heeg JE; Scheffer H; de Zeeuw D; de Jong PE
    Nephrol Dial Transplant; 1997; 12 Suppl 2():42-6. PubMed ID: 9269699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies.
    Ruggenenti P; Pagano E; Tammuzzo L; Benini R; Garattini L; Remuzzi G
    Kidney Int; 2001 Jan; 59(1):286-94. PubMed ID: 11135082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of pharmacogenetic testing to predict treatment response to angiotensin-converting enzyme inhibitor.
    Costa-Scharplatz M; van Asselt AD; Bachmann LM; Kessels AG; Severens JL
    Pharmacogenet Genomics; 2007 May; 17(5):359-68. PubMed ID: 17429318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of angiotensin-converting enzyme gene polymorphism on the progression of immunoglobulin A nephropathy in Malaysian patients.
    Draman CR; Kong NC; Gafor AH; Rahman AF; Zainuddin S; Mustaffa WM; Radzi AM; Shamsul AS
    Singapore Med J; 2008 Nov; 49(11):924-9. PubMed ID: 19037561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.